1. Generics Bulletin
  2. >>Products

Walmart Partners With Novo Nordisk To Launch US Private-Label Insulin

Company Launches Insulin Aspart And FlexPens As Interchangeable Biosimilars Loom

 
• By Akriti Seth

Walmart, the famous American multinational retailer, has launched what it is billing as the “first and only” private brand analog insulin, under the company’s brand ReliOn, in partnership with Novo Nordisk. The firm is offering ReliOn NovoLog (insulin aspart) vials and FlexPen in its pharmacies immediately. 

Walmart
Walmart says it aims to increase access and affordability through its private brand analog insulin launch • Source: Alamy

Walmart has recently announced the launch of the “first and only” private brand analog insulin, under the company’s brand ReliOn, in partnership with Novo Nordisk. The firm is offering NovoLog (insulin aspart) vials priced at $72.88 and FlexPenpriced at $85.88, in a move that the retailer says is expected to “revolutionize the access and affordability to diabetes care by offering customers significant price savings without compromising quality.”

Commenting on Walmart’s new launch, Cheryl Pegus, executive vice president of Walmart health & wellness said, “With ReliOn NovoLog insulin, we’re adding a high-quality medication for diabetes to the already affordable ReliOn line of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

More from Generics Bulletin

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Medicines UK Welcomes NHS England’s Best-Value Biologics Biosimilar Adoption Framework

 
• By Adam Zamecnik

Reflecting on recent initiatives by NHS England and the MHRA, the newly renamed trade body Medicines UK has welcomed efforts in promoting the use of biosimilars in Britain.